Binding of Dopamine D1 Receptor and Noradrenaline Transporter in Individuals with Autism Spectrum Disorder: A PET Study.

Autor:	Kubota M; Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Chiba 263-8555, Japan.; Medical Institute of Developmental Disabilities Research, Showa University, Tokyo 157-8577, Japan.; Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan., Fujino J; Medical Institute of Developmental Disabilities Research, Showa University, Tokyo 157-8577, Japan.; Department of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, Japan., Tei S; Medical Institute of Developmental Disabilities Research, Showa University, Tokyo 157-8577, Japan.; Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.; Institute of Applied Brain Sciences, Waseda University, Saitama 359-1192, Japan.; School of Human and Social Sciences, Tokyo International University, Saitama 350-1198, Japan., Takahata K; Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Chiba 263-8555, Japan.; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo 160-8582, Japan., Matsuoka K; Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Chiba 263-8555, Japan., Tagai K; Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Chiba 263-8555, Japan., Sano Y; Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Chiba 263-8555, Japan.; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo 160-8582, Japan., Yamamoto Y; Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Chiba 263-8555, Japan.; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo 160-8582, Japan., Shimada H; Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Chiba 263-8555, Japan., Takado Y; Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Chiba 263-8555, Japan., Seki C; Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Chiba 263-8555, Japan., Itahashi T; Medical Institute of Developmental Disabilities Research, Showa University, Tokyo 157-8577, Japan., Aoki YY; Medical Institute of Developmental Disabilities Research, Showa University, Tokyo 157-8577, Japan., Ohta H; Medical Institute of Developmental Disabilities Research, Showa University, Tokyo 157-8577, Japan.; Department of Psychiatry, School of Medicine, Showa University, Tokyo 157-8577, Japan., Hashimoto RI; Medical Institute of Developmental Disabilities Research, Showa University, Tokyo 157-8577, Japan.; Department of Language Sciences, Graduate School of Humanities, Tokyo Metropolitan University, Tokyo 192-0397, Japan., Zhang MR; Department of Radiopharmaceuticals Development, National Institute of Radiological Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Chiba 263-8555, Japan., Suhara T; Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Chiba 263-8555, Japan., Nakamura M; Medical Institute of Developmental Disabilities Research, Showa University, Tokyo 157-8577, Japan.; Kanagawa Psychiatric Center, Yokohama, Kanagawa 233-0006, Japan., Takahashi H; Medical Institute of Developmental Disabilities Research, Showa University, Tokyo 157-8577, Japan.; Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.; Department of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, Japan., Kato N; Medical Institute of Developmental Disabilities Research, Showa University, Tokyo 157-8577, Japan., Higuchi M; Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Chiba 263-8555, Japan.
Jazyk:	angličtina
Zdroj:	Cerebral cortex (New York, N.Y. : 1991) [Cereb Cortex] 2020 Nov 03; Vol. 30 (12), pp. 6458-6468.
DOI:	10.1093/cercor/bhaa211
Abstrakt:	Although previous studies have suggested the involvement of dopamine (DA) and noradrenaline (NA) neurotransmissions in the autism spectrum disorder (ASD) pathophysiology, few studies have examined these neurotransmissions in individuals with ASD in vivo. Here, we investigated DA D1 receptor (D1R) and noradrenaline transporter (NAT) binding in adults with ASD (n = 18) and neurotypical controls (n = 20) by utilizing two different PET radioligands, [11C]SCH23390 and (S,S)-[18F]FMeNER-D2, respectively. We found no significant group differences in DA D1R (striatum, anterior cingulate cortex, and temporal cortex) or NAT (thalamus and pons) binding. However, in the ASD group, there were significant negative correlations between DA D1R binding (striatum, anterior cingulate cortex and temporal cortex) and the "attention to detail" subscale score of the Autism Spectrum Quotient. Further, there was a significant positive correlation between DA D1R binding (temporal cortex) and emotion perception ability assessed by the neurocognitive battery. Associations of NAT binding with empathic abilities and executive function were found in controls, but were absent in the ASD group. Although a lack of significant group differences in binding might be partly due to the heterogeneity of ASD, our results indicate that central DA and NA function might play certain roles in the clinical characteristics of ASD. (© The Author(s) 2020. Published by Oxford University Press.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu